EXPLORING THE COMPLEX RELATIONSHIP BETWEEN INSULIN RESISTANCE, LIPID METABOLISM, AND CARDIOVASCULAR RISK

Main Article Content

Muhammad Nouman Majeed
Asif Khan
Dr. Hira Amin
Bijaya Bhattarai
Dr. Abdul Wadood Kakar
Dr. Adut Matik
Subhan Haider
Mr. V. Sampath
Rubaiya Tabassum
Tariq Rafique

Keywords

Diabetes, cardiovascular disease, insulin resistance, dyslipidemia, atherogenesis, hyperglycemia, oxidative stress

Abstract

Background:

Cardiovascular disease (CVD) is a predominant concern for individuals diagnosed with diabetes mellitus, representing a leading cause of morbidity and mortality. This review delves into the complex interplay between diabetes and cardiovascular problems, offering insights into preventative interventions and treatment strategies.


 
Methods:

Drawing from current research, this comprehensive review evaluates methods to reduce cardiovascular risk in individuals with diabetes. The analysis focuses on insulin resistance as a pivotal factor linking diabetes to CVD, leading to dyslipidemia and atherogenesis, thereby elevating the risk of cardiovascular events.


 
Results:

Patients with diabetes face an increased risk of cardiovascular events due to the intricate relationship between insulin resistance, dyslipidemia, and atherogenesis. Moreover, hyperglycemia-induced oxidative stress and inflammation contribute to endothelial dysfunction, fostering vascular damage and elevating the risk of cardiovascular issues. The correlation between diabetes and CVD accelerates atherosclerotic plaque formation, rendering the plaque more prone to rupture and causing severe cardiovascular problems like myocardial infarction and stroke.


 
Conclusion:

Understanding the nuanced connection between diabetes and cardiovascular disease is paramount for developing effective interventions. This narrative review synthesizes evidence-based preventative measures and treatment choices, providing valuable insights for healthcare practitioners. The aim is to enhance patient outcomes, improve quality of life, and reduce mortality rates in individuals with diabetes and coexisting CVD. The review serves as a comprehensive resource for healthcare professionals and academics, laying the groundwork for innovative approaches in diabetes management through an in-depth exploration of current research and underlying processes.

Abstract 456 | pdf Downloads 154

References

A
1. agaard, A., & Rezac, F. (2022). Governing the interplay of inter-organizational relationship mechanisms in open innovation projects across ecosystems. Industrial Marketing Management, 105, 131-146.
2. Abdelhamid, A. A., Eid, M. M., Abotaleb, M., & Towfek, S. (2023). Identification of cardiovascular disease risk factors among diabetes patients using ontological data mining techniques. Journal of Artificial Intelligence and Metaheuristics, 4(2), 45-53.
3. Aimo, A., Pascual-Figal, D. A., Barison, A., Cediel, G., Vicente, Á. H., Saccaro, L. F., . . . Bayes-Genis, A. (2021). Colchicine for the treatment of coronary artery disease. Trends in cardiovascular medicine, 31(8), 497-504.
4. Andersson, N. W., Corn, G., Dohlmann, T. L., Melbye, M., Wohlfahrt, J., & Lund, M. (2023). LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals. Journal of the American College of Cardiology, 82(14), 1381-1391.
5. Cases, A. (2023). Glucagon-like peptide 1 (GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist. Nefrología (English Edition).
6. De Servi, S., Landi, A., Savonitto, S., De Luca, L., De Luca, G., Morici, N., . . . Cattaneo, M. (2023). Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice. Journal of Cardiovascular Medicine, 24(2), 77-86.
7. Deslippe, A. L., Soanes, A., Bouchaud, C. C., Beckenstein, H., Slim, M., Plourde, H., & Cohen, T. R. (2023). Barriers and facilitators to diet, physical activity and lifestyle behavior intervention adherence: a qualitative systematic review of the literature. International Journal of Behavioral Nutrition and Physical Activity, 20(1), 1-25.
8. Dewi, D. K., Sekartini, R., Sunardi, D., Soewondo, P., Yunir, E., Widyahening, I. S., . . . Vidiawati, D. (2023). The effectiveness of self-empowerment-based patient-centered care for obese students in primary services: A randomized controlled trial. Journal of Family & Community Medicine, 30(1), 51.
9. Do, D. V., Han, G., Abariga, S. A., Sleilati, G., Vedula, S. S., & Hawkins, B. S. (2023). Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews(3).
10. Faheem, O., & Zafar, A. B. (2024). Macrovascular complications: Coronary artery disease. In BIDE's Diabetes Desk Book (pp. 201-219): Elsevier.
11. Gao, H., Yous, M.-L., Connelly, D., Hung, L., Garnett, A., Hay, M., & Snobelen, N. (2023). Implementation and impacts of virtual team-based care planning for older persons in formal care settings: A scoping review. Digital Health, 9, 20552076231151567.
12. Goldney, J., Sargeant, J. A., & Davies, M. J. (2023). Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia, 66(10), 1832-1845.
13. Greene, S. J., Bauersachs, J., Brugts, J. J., Ezekowitz, J. A., Lam, C. S., Lund, L. H., . . . Zieroth, S. (2023). Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week. Journal of the American College of Cardiology, 81(4), 413-424.
14. Gusev, E., & Sarapultsev, A. (2023). Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. International Journal of Molecular Sciences, 24(9), 7910.
15. Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., . . . Inagaki, N. (2023). Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. Cardiovascular Diabetology, 22(1), 62.
16. Hassan, S., Gujral, U. P., Quarells, R. C., Rhodes, E. C., Shah, M. K., Obi, J., . . . Narayan, K. V. (2023). Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward. The Lancet Diabetes & Endocrinology.
17. Ilie, G., Rendon, R., Mason, R., MacDonald, C., Kucharczyk, M. J., Patil, N., . . . Lawen, J. (2023). A comprehensive 6-mo prostate cancer patient empowerment program decreases psychological distress among men undergoing curative prostate cancer treatment: a randomized clinical trial. European Urology, 83(6), 561-570.
18. Jutten, R. J., Papp, K. V., Hendrix, S., Ellison, N., Langbaum, J. B., Donohue, M. C., . . . Harrison, J. (2023). Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. Alzheimer's & Dementia, 19(2), 708-720.
19. Jyotsna, F., Ahmed, A., Kumar, K., Kaur, P., Chaudhary, M. H., Kumar, S., . . . Varrassi, G. (2023). Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes. Cureus, 15(8).
20. Klonoff, A. N., Lee, W.-A., Xu, N. Y., Nguyen, K. T., DuBord, A., & Kerr, D. (2023). Six digital health technologies that will transform diabetes. Journal of diabetes science and technology, 17(1), 239-249.
21. Kumari, Y., Bai, P., Waqar, F., Asif, A. T., Irshad, B., Raj, S., . . . Chand, S. (2023). Advancements in the management of endocrine system disorders and arrhythmias: a comprehensive narrative review. Cureus, 15(10).
22. Palmer, B. F., & Clegg, D. J. (2023). Kidney-protective effects of SGLT2 inhibitors. Clinical Journal of the American Society of Nephrology, 18(2), 279-289.
23. Philibert, R., Moody, J., Philibert, W., Dogan, M. V., & Hoffman, E. A. (2023). The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation. Genes, 14(6), 1233.
24. Strauss, M. H., Hall, A. S., & Narkiewicz, K. (2023). ACEI and ARB—Each Unique RAAS Inhibitors: The Importance of Impact on Inflammation. Paper presented at the Mayo Clinic Proceedings.
25. Sumner, J. A., Cleveland, S., Chen, T., & Gradus, J. L. (2023). Psychological and biological mechanisms linking trauma with cardiovascular disease risk. Translational Psychiatry, 13(1), 25.
26. Violi, F., Cammisotto, V., Bartimoccia, S., Pignatelli, P., Carnevale, R., & Nocella, C. (2023). Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. Nature Reviews Cardiology, 20(1), 24-37.

Most read articles by the same author(s)

1 2 3 > >>